Meeting
2018 ASCO Annual Meeting
NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).
Authors
Jame Abraham
NSABP Foundation and Cleveland Clinic, Cleveland, OH
Jame Abraham , Shannon Puhalla , William M. Sikov , Alberto J. Montero , Mohamad Adham Salkeni , Wajeeha Razaq , Jan Hendrik Beumer , Brian Kiesel , Marc E. Buyse , Laura M Adamson , Ashok Srinivasan , Katherine L. Pogue-Geile , Carmen Joseph Allegra , Samuel A. Jacobs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02236000
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1027)
DOI
10.1200/JCO.2018.36.15_suppl.1027
Abstract #
1027
Poster Bd #
108
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton
Poster
2023 ASCO Breakthrough
Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.
First Author: WanChen Hsieh
Poster
2023 ASCO Annual Meeting
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
First Author: Anna-Maria Lazaratos
Poster
2020 ASCO Virtual Scientific Program
A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).
First Author: Adrienne Gropper Waks